The Actos Safety Review: What is it all about?

In September 2010, the Food and Drug Administration ordered a safety review of Actos based on preliminary data indicating a possible risk of bladder cancer. The FDA is reviewing data from an ongoing ten-year study to evaluate bladder cancer risk, after findings in animal and human studies suggested a need for further evaluation. The ten-year study is observing the long-term risk of bladder cancer associated with Actos in approximately 193,000 diabetic patients. The five-year results so far have shown no overall increased risk of bladder cancer from Actos use.

Takeda Actos

However, a significantly increased risk of bladder cancer has been associated with patients taking the highest Actos dosages and with patients taking Actos over the longest periods of time. Based on its safety review, the FDA has required updated Actos drug label warnings and is informing the public that taking Actos for more than one year may be associated with an increased risk of bladder cancer.

The FDA will continue to update the public on the results of its review and as new data becomes available.

To tell us about your case, please fill out the 'Free Consultation' form in the right pane.

● Helpful Articles

Free Consultation  Call Now

Get Interactive

Sullo & Sullo-Facebook Sullo & Sullo-Linkedin Sullo & Sullo-Twitter Sullo & Sullo-You Tube
Free Consultation
Receive an immediate response to your request.
Choose the Practice Area of Your Problem:

I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared. I further understand and agree to the Terms of Use and Privacy Policy

Enter the code shown above in the box below

Recent Articles & Publications

January 29, 2013
Actos—pioglitazone—is one of the best-selling drugs in the United States, used in the treatment of Type 2 diabetes. Actos gained FDA approval some thirteen years ago, and...

January 28, 2013
Actos is a drug frequently prescribed for those with Type 2 diabetes. Takeda, a Japanese pharmaceutical company, began manufacturing Actos in 1999.

January 28, 2013
Actos (pioglitazone) is a prescription drug used in the treatment of Type 2 Diabetes. Approved in 1999, the drug has been on the market for over thirteen years, and at one...